$NVO Cuts FY25 EBIT +10-16%, Rev +8-14% y/y (prior Rev growth +13-21% (cc) y/y, Op growth +16-24% (cc)); Notes lower volume growth of GLP-1-based treatments in the US and related cash flow implications amplified by the US gross-to-net system (Novo Nordisk A/S) (More at

$SOFI Reports Q2 $0.08 v $0.06e, Rev $858.2M v $805Me; Raises again outlook; Accelerated adjusted net Rev growth to 44%, the highest level in over two years (SoFi Technologies Inc) - Raises FY25 GAAP EPS $0.31 v $0.28e, Rev $3.38B v $3.29Be, GAAP Net $370M, adj EBITDA $960M,

$PYPL Reports Q2 $1.40 v $1.30e, Rev $8.29B v $8.10Be; Raises EPS outlook (PayPal Holdings Inc) - Guides Q3 adj EPS $1.18-1.22 v $1.21e - Raises FY25 adj EPS growth $5.15-5.30 +11-14% y/y v $5.10e (prior: $4.95-5.10) - Guides Q3 Transaction margin $3.76-3.82B, +5-7% adj growth;

$NVO Cuts outlook; For Wegovy in the US, the sales outlook reflects the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition (Novo Nordisk A/S) $LLY - The lowered sales outlook for 2025 is driven by lower growth expectations for the second

$BA Reports Q2 -$1.24 v -$1.54e, Rev $22.7B v $21.9Be; Confirms 737 production reached 38 per month in the quarter; 787 program production rate is now at seven per month (The Boeing Company) - Free cash flow -$200M v -$2.29B q/q v -$1.79Be - Op cash flow +$0.2B v -$3.92B y/y

$NVO Names Maziar Mike Doustdar appointed as Pres and CEO; effective Aug 7th; Research & Early Development and Development EVP areas will be merged into a combined R&D unit (Novo Nordisk A/S) (More at tradethenews.com/?twtId=52116)

$UNH TTN Summary of 08:00ET Earnings Call: Adjusted 2025 earnings outlook reflects $6.5 billion incremental medical cost pressurevs. initial forecast: $3.6 billion in Medicare, $2.3 billion in commercial (split evenly between ACA and employer), remainder in Medicaid driven by

Upside: $DRRX +264% (BHC to acquire DRRX for upfront consideration of ~$63M at closing, with the potential for two additional net sales milestone payments of up to $350M) $CLDI +43% (receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded

*(CN) CHINA ALERTS TSUNAMI MAY HAVE 'DISASTROUS IMPACT ON ITS COAST (More at tradethenews.com/?twtId=52119)

*(RU) RUSSIAN STATE OF EMERGENCY DECLARED ON TSUNAMI HIT ISLANDS (More at tradethenews.com/?twtId=52120)

*(ES) SPAIN JULY PRELIMINARY CPI M/M: -0.1% V -0.4%E; Y/Y: 2.7% V 2.4%E (highest annual pace since Feb and 4th straight month of reacceleration) - CPI Core Y/Y: 2.3% v 2.2%e (More at tradethenews.com/?twtId=52122)

*(DE) GERMANY Q2 PRELIMINARY GDP Q/Q: -0.1% V -0.1%E; Y/Y: 0.4% V 0.2%E (1st positive Y/Y growth since Q4 2022) *(IT) ITALY Q2 PRELIMINARY GDP Q/Q: -0.1% V +0.1%E; Y/Y: 0.4% V 0.6%E (More at tradethenews.com/?twtId=52123)

$VRT Reports Q2 $0.95 v $0.83e, Rev $2.64B v $2.28Be; Raises outlook; "What we're seeing in the data center industry today goes well beyond the next few years" (Vertiv Holdings Co) - Guides Q3 Adj EPS $0.94-1.00 v $0.95e, Rev $2.51-2.59B v $2.44Be, Organic Rev +20-24%, Adj Op

$VRT Q2 Book-to-bill 1.2x v 1.4x q/q; Pricing continues to be favorable. 2025 pricing expected to exceed 2025 inflation including any projected secondary impact from tariffs - earnings slides (Vertiv Holdings Co) - Tariffs a significant margin headwind vs. prior year (More at

$HSY Guides FY25 adj Gross margin -700bps to -675bps; Without tariffs, we would have raised our full year adjusted EPS outlook - prepared remarks (The Hershey Company) - Given the unique circumstances surrounding cocoa, which cannot be grown in the United States, we remain

$ETSY Reports Q2 $0.25 (unclear if comp) v $0.54e, Rev $672.7M v $648Me; Guides Q3 below est (Etsy Inc) - Guides Q3 adj EBITDA margin 25% v 26.2%e, GMS $2.6-2.7B v $2.7Be - GMS $2.81B, -4.8% y/y (cc) - Active Sellers 8.1M, -7.8% y/y - Active Buyers 93.3M -3.4% y/y v 94.5Me - Adj

*(US) PRES. TRUMP: INDIA WILL BE PAYING A TARIFF OF 25%, PLUS A PENALTY FOR THE ABOVE, STARTING ON AUGUST FIRST. THANK YOU FOR YOUR ATTENTION TO THIS MATTER. - Remember, while India is our friend, we have, over the years, done relatively little business with them because their

*(US) Q2 ADVANCE GDP ANNUALIZED Q/Q: 3.0% V 2.6%E (biggest Q/Q rise since Q3 2024; imports recorded big drop); PERSONAL CONSUMPTION: 1.4% V 1.5%E *(US) Q2 ADVANCE GDP PRICE INDEX: 2.0% V 2.2%E; CORE PCE PRICE INDEX Q/Q: 2.5% V 2.3%E (More at tradethenews.com/?twtId=52129)

Upside: $LC +24% (earnings, guidance) $WING +21% (earnings, guidance; raises dividend) $VFC +19% (earnings, guidance) $HOG +14% (earnings) $CGON +9.7% (Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI

(US) TTN Reminder: Pres Trump's tariff maximalism set to meet the major‑questions Court on July 31st - the lead test of whether the International Emergency Economic Powers Act (IEEPA) lets a president rewrite the tariff schedule by declaring a national emergency - Possible